Tioconazolum [INN-Latin] en es it fr

Tioconazolum [INN-Latin] Brand names, Tioconazolum [INN-Latin] Analogs

Tioconazolum [INN-Latin] Brand Names Mixture

  • No information avaliable

Tioconazolum [INN-Latin] Chemical_Formula


Tioconazolum [INN-Latin] RX_link


Tioconazolum [INN-Latin] fda sheet

Tioconazolum [INN-Latin] msds (material safety sheet)

Tioconazolum_[INN-Latin] MSDS

Tioconazolum [INN-Latin] Synthesis Reference

No information avaliable

Tioconazolum [INN-Latin] Molecular Weight

157.21 g/mol

Tioconazolum [INN-Latin] Melting Point

>300 oC

Tioconazolum [INN-Latin] H2O Solubility

1.67E+005 mg/L

Tioconazolum [INN-Latin] State


Tioconazolum [INN-Latin] LogP


Tioconazolum [INN-Latin] Dosage Forms

Tablets containing 500 mg of tranexamic acid; Sterile solution for intravenous injection containing 100 mg tranexamic acid

Tioconazolum [INN-Latin] Indication

For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

Tioconazolum [INN-Latin] Pharmacology

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).

Tioconazolum [INN-Latin] Absorption

Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.

Tioconazolum [INN-Latin] side effects and Toxicity

Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.

Tioconazolum [INN-Latin] Patient Information

Tioconazolum [INN-Latin] Organisms Affected

Humans and other mammals